glp 1 and heart health GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, Emerging Therapies GLP-1 Therapies And Lifestyle Changes:
Description
Conclusion In summary, the results of this population based study, designed to closely emulate a randomised controlled trial, suggest that the use of the GLP-1 receptor agonist-SGLT-2 inhibitor combination is associated with a lower risk of major adverse cardiovascular events and serious renal events among patients with type 2 diabetes compared with each drug class alone
The financial reality of American healthcare today is sobering: Every day, 1 in 2 Americans choose between paying medical bills and covering basic needs
How is Exendin-4/Exenatide having this positive effect
, Stadlbauer, U
